| Literature DB >> 32552256 |
Abstract
Acute disseminated encephalomyelitis (ADEM) was originally described in the medical literature more than 200 years ago. However, consensus clinical diagnostic criteria are less than 15 years old. Accurate diagnostic testing for myelin oligodendrocyte glycoprotein (MOG) autoantibodies has only become clinically available in the last 3-5 years and has facilitated a rapidly evolving understanding of patients with recurrent demyelination following ADEM. The field is working to optimize treatment for these patients with hopes of prospective treatment studies in the not too distant future. New imaging data suggest that even monophasic demyelination may have long-term impacts that were previously unrecognized. Recent developments in the literature are described in order to guide practice for providers who treat both adults and children with monophasic and recurrent forms of ADEM with and without MOG antibodies.Entities:
Keywords: ADEM; MOG; acute disseminated encephalomyelitis; demyelinating autoimmune diseases CNS; demyelinating diseases; myelin oligodendrocyte glycoprotein
Year: 2020 PMID: 32552256 DOI: 10.1177/1352458520929627
Source DB: PubMed Journal: Mult Scler ISSN: 1352-4585 Impact factor: 6.312